North America Human Insulin Drugs Market Size
|Study Period:||2018 - 2028|
|CAGR:||> 4 %|
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and it's growth?
North America Human Insulin Drugs Market Analysis
The North America Human Insulin Drugs Market size was valued at USD 10.69 billion in 2022, and is expected to reach USD 13.50 billion by 2028, growing at a CAGR of 3.91% during the forecast period (2023-2028).
In North America diabetes incidence for type 2 diabetes as well as other diabetes, forms were numerically higher in individuals with Covid-19. Insulin resistance and impaired insulin secretion have been described in individuals without diabetes history who recovered from SARS-CoV-2 infections. It has been suggested that diagnosis and treatment of post-Covid syndrome require integrated rather than disease-specific approaches.
North America dominates the global insulin therapeutics market, owing to the high prevalence of diabetes in the region because of the sedentary lifestyle and the launch of new drugs in the region. The United States is expected to grow tremendously during the forecast period, owing to factors, such as the high prevalence of obesity and increasing awareness regarding diabetes care in the region.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
North America Human Insulin Drugs Industry Segmentation
North America's human insulin drug market will witness USD 10 billion in the current year and is anticipated to register a CAGR of over 4% during the forecast period. The North American human insulin drug market is segmented by drug (basal or long-acting insulin, bolus or fast-acting insulin, traditional human insulin, combination insulin, and biosimilar insulin) and geography (United States, Canada, and rest of North America). The report offers the value (in USD million) and volume (in units million) for the above segments. This report will provide a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.
|Rest of North America|
North America Human Insulin Drugs Market Trends
Basal/Long Acting Insulins Holds The Highest Market Share in Current Year
The US Food and Drug Administration (FDA) approved Lantus in April 2000. Lantus is a man-made form of the hormone insulin that is produced in the body. Insulin is a hormone that works by lowering levels of glucose (sugar) in the blood. Insulin glargine is a long-acting insulin that starts to work several hours after injection and keeps working evenly for 24 hours. Lantus is for use in adults with type-1 or type-2 diabetes and in children at least 6 years old with type-1 diabetes. For type-1 diabetes, Lantus is used together with short-acting insulin given before meals. Lantus and Januvia, two treatments for diabetes, are some of the highest-selling drugs of all time and represent some of the greatest breakthroughs in diabetes control.
In 2021, the United States was the largest market for Lantus, accounting for more than 58% of market revenues. However, the biosimilars for Lantus may not present it with competitive challenges currently. The loss of exclusivity for Lantus may not result in a near-term disruption of the market for it. However, there will be additional pricing pressure and some loss of market share that will continue and may increase over time.
To understand key trends, Download Sample Report
United States Holds Highest Market Share in Current Year
Among North American countries, the United States dominates around 94% of the total North American human insulin drug market. This is mainly due to the high diabetes prevalence in the country. The United States records the highest healthcare expenditure globally, and it also has a higher adoption of advanced therapeutics. The United States accounts for the highest sales of long-acting insulin, Lantus, across the North American region. Most diabetic drug manufacturing companies consider the country a critical market for improving overall global sales. Lantus is the most commonly administered basal insulin across the world, accounting for a dominant share in the United States market. Together, Eli Lilly and Boehringer Ingelheim are working to develop and market Basaglar (Insulin Glargine). Insulin Tregopil, an oral prandial insulin tablet, is being developed by Biocon to treat type-1 and type-2 diabetes mellitus. Fast-acting oral insulin holds the potential to revolutionize T1D care by enhancing post-prandial glucose control with fewer side effects and higher adherence. In order to provide a more practical, efficient, and secure way to administer insulin therapy, Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is attempting to bring the first oral insulin product to market.
The United States accounts for the highest sales of Humalog across the world, with over 56% of the market share. The majority of diabetes drug manufacturing companies consider the country a critical market for improving overall global sales. In the United States, Humalog is available in different varieties under names like Humalog Mix 75/25, Humalog U-100, Humalog U-200, and Humalog Mix 50/50 for the treatment of diabetes.
Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the North American region.
To understand geography trends, Download Sample Report
North America Human Insulin Drugs Industry Overview
The North American human insulin market is highly fragmented, with three major manufacturers having a large market share. In the United States, there are no other players except Novo Nordisk, Sanofi, and Eli Lilly. In the remaining countries, the manufacturers confine themselves to other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance to develop and commercialize Basaglar (insulin glargine).
North America Human Insulin Drugs Market Leaders
Novo Nordisk A/S
Eli Lilly and Company
*Disclaimer: Major Players sorted in no particular order
North America Human Insulin Drugs Market News
- November 2022: The FDA approved the second interchangeable insulin glargine biosimilar, Rezvoglar, to improve glycemic control in adults and pediatric patients with diabetes, according to a drug information update from the agency.
- October 2022: Novo Nordisk announced headline results from the ONWARDS 5 phase 3a trial with once-weekly insulin icodec in people with type-2 diabetes. The ONWARDS 5 trial was a 52-week, open-label efficacy, and safety treat-to-target trial investigating once-weekly insulin versus once-daily basal insulin (insulin degludec or insulin glargine U100/U300).
North America Human Insulin Drugs Market Report - Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1.1 Basal or Long-acting Insulin
18.104.22.168 Lantus (Insulin Glargine)
22.214.171.124 Levemir (Insulin Detemir)
126.96.36.199 Toujeo (Insulin Glargine)
188.8.131.52 Tresiba (Insulin Degludec)
184.108.40.206 Basaglar (Insulin Glargine)
5.1.2 Bolus or Fast-acting Insulin
220.127.116.11 NovoRapid/Novolog (Insulin Aspart)
18.104.22.168 Humalog (Insulin Lispro)
22.214.171.124 Apidra (Insulin Glulisine)
126.96.36.199 FIASP (Insulin aspart)
188.8.131.52 Admelog (Insulin lispro)
5.1.3 Traditional Human Insulin
5.1.4 Combination Insulin
184.108.40.206 NovoMix (Biphasic Insulin Aspart)
220.127.116.11 Ryzodeg (Insulin Degludec and Insulin Aspart)
18.104.22.168 Xultophy (Insulin Degludec and Liraglutide)
22.214.171.124 Soliqua/Suliqua (Insulin glargine/Lixisenatide)
5.1.5 Biosimilar Insulin
126.96.36.199 Insulin Glargine Biosimilars
188.8.131.52 Human Insulin Biosimilars
5.2.1 United States
5.2.3 Rest of North America
6. MARKET INDICATORS
6.1 Type 1 Diabetes Population
6.2 Type 2 Diabetes Population
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk A/S
7.1.2 Sanofi S.A.
7.1.3 Eli Lilly and Company
7.1.4 Biocon Limited
7.1.5 Pfizer Inc.
- *List Not Exhaustive
7.2 COMPANY SHARE ANALYSIS
7.2.1 Novo Nordisk AS
7.2.2 Sanofi S.A.
7.2.3 Eli Lilly and Company
7.2.4 Other Companies
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
North America Human Insulin Drugs Market Research FAQs
What is the study period of this market?
The North America Human Insulin Drugs Market is studied from 2018 - 2028.
What is the growth rate of North America Human Insulin Drugs Market?
The North America Human Insulin Drugs Market is growing at a CAGR of >4% over the next 5 years.
What is North America Human Insulin Drugs Market size in 2018?
The North America Human Insulin Drugs Market is valued at 10 Billion USD in 2018.
What is North America Human Insulin Drugs Market size in 2028?
The North America Human Insulin Drugs Market is valued at 13 Billion USD in 2028.
Who are the key players in North America Human Insulin Drugs Market?
Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc, Biocon Limited are the major companies operating in North America Human Insulin Drugs Market.
North America Human Insulin Drugs Industry Report
Statistics for the 2023 North America Human Insulin Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. North America Human Insulin Drugs analysis includes a market forecast outlook to for 2023 to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.